An Efficacy Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT01060150 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

115

Enrollment

INDUSTRY

Sponsor class

Conditions

Attention Deficit Disorder With Hyperactivity

Interventions

DRUG: OROS Methylphenidate HCl

Sponsor

Janssen Korea, Ltd., Korea